SECISBP2L and Miyoshi myopathy: In contrast to cMo, no significant differences were observed between the different patient groups and HD as regards both iMo and ncMo counts in blood (Figure 3F–K), except for decreased ncMo -median (range)- levels in MM -23 (4–71) cells/μL vs. 37 (11–84) cells/μL (p = 0.01)- (Figure 3G), at the expense of the CD36−Slan−, CD36+Slan+ and CD36−Slan+ subsets of ncMo −7 (1–31) cells/μL, 0.6 (0–5) cells/μL and 3 (0–18) cells/μL vs. 11 (2–43) cells/μL, 1.8 (0.3–5) cells/μL and 9 (3–24) cells/μL in HD, respectively (p ≤ 0.05)-.